• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过对纵向生物标志物进行建模来检测多个时间点的参与者不依从性。

Detecting participant noncompliance across multiple time points by modeling a longitudinal biomarker.

机构信息

Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

Division of Addiction Sciences, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.

出版信息

Clin Trials. 2021 Feb;18(1):28-38. doi: 10.1177/1740774520956949. Epub 2020 Sep 14.

DOI:10.1177/1740774520956949
PMID:32921152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9364488/
Abstract

INTRODUCTION

Participant noncompliance, in which participants do not follow their assigned treatment protocol, has long complicated the interpretation of randomized clinical trials. No gold standard has been identified for detecting noncompliance, but in some trials participants' biomarkers can provide objective information that suggests exposure to non-study treatments. However, existing methods are limited to retrospectively detecting noncompliance at a single time point based on a single biomarker measurement. We propose a novel method that can leverage participants' full biomarker history to detect noncompliance across multiple time points. Conditional on longitudinal biomarker data, our method can estimate the probability of compliance at (1) a single time point of the trial, (2) all time points, and (3) a future time point.

METHODS

Across time points, we model the biomarker as a mixture density with (latent) components corresponding to longitudinal patterns of compliance. To estimate the mixture density, we fit mixed effects models for both compliance and the biomarker. We use the mixture density to derive compliance probabilities that condition on the longitudinal biomarker data. We evaluate our compliance probabilities by simulation and apply them to a trial in which current smokers were asked to only smoke low nicotine study cigarettes (Center for the Evaluation of Nicotine in Cigarettes Project 1 Study 2). In the simulation, we investigated three different effects of compliance on the biomarker, as well as the effect of misspecification of the covariance structures. We compared probability estimators (1) and (2) to those that ignore the longitudinal correlation in the data according to area under the receiver operating characteristic curve. We evaluated estimator (3) by plotting its calibration lines. For Center for the Evaluation of Nicotine in Cigarettes Project 1 Study 2, we compared estimators (1) and (3) to a probability estimator of compliance at the last time point that ignores the longitudinal correlation.

RESULTS

In the simulation, for both compliance at the last time point and at all time points, conditioning on the longitudinal biomarker data uniformly raised area under the receiver operating characteristic curve across all three compliance effect scenarios. The gains in area under the receiver operating characteristic curve were smaller under misspecification. The calibration lines for the prediction of compliance closely followed 45°, though with additional variability under misspecification. For compliance at the last time point of Center for the Evaluation of Nicotine in Cigarettes Project 1 Study 2, conditioning on participants' full biomarker history boosted area under the receiver operating characteristic curve by three percentage points. The prediction probabilities somewhat accurately approximated the non-longitudinal compliance probabilities.

DISCUSSION

Compared to existing methods that only use a single biomarker measurement, our method can account for the longitudinal correlation in the biomarker and compliance to more accurately identify noncompliant participants. Our method can also use participants' biomarker history to predict compliance at a future time point.

摘要

简介

参与者不遵守规定(即参与者不遵循其指定的治疗方案)长期以来一直使随机临床试验的解释变得复杂。虽然没有确定检测不遵守规定的黄金标准,但在某些试验中,参与者的生物标志物可以提供表明接触非研究治疗的客观信息。然而,现有的方法仅限于基于单次生物标志物测量在单个时间点上回顾性地检测不遵守规定的情况。我们提出了一种新方法,可以利用参与者的全部生物标志物历史在多个时间点上检测不遵守规定的情况。在有纵向生物标志物数据的情况下,我们的方法可以估计(1)试验中的单个时间点、(2)所有时间点和(3)未来时间点的合规概率。

方法

在不同的时间点,我们将生物标志物建模为混合密度,其中(潜在)成分对应于合规的纵向模式。为了估计混合密度,我们为合规性和生物标志物拟合混合效应模型。我们使用混合密度来推导出基于纵向生物标志物数据的合规概率。我们通过模拟评估我们的合规概率,并将其应用于一项当前吸烟者被要求仅吸低尼古丁研究香烟的试验(尼古丁在香烟中评估中心项目 1 研究 2)。在模拟中,我们研究了三种不同的合规性对生物标志物的影响,以及协方差结构指定不正确的影响。我们根据接收器操作特性曲线下的面积将概率估计器(1)和(2)与那些忽略数据中纵向相关性的估计器进行比较。我们通过绘制校准线来评估估计器(3)。对于尼古丁在香烟中评估中心项目 1 研究 2,我们将估计器(1)和(3)与忽略纵向相关性的最后时间点的合规概率估计器进行了比较。

结果

在模拟中,对于最后时间点和所有时间点的合规性,根据纵向生物标志物数据进行条件处理,在所有三种合规性效果情况下都均匀提高了接收器操作特性曲线下的面积。在协方差结构指定不正确的情况下,接收者操作特性曲线下的面积增益较小。合规性预测的校准线非常接近 45°,尽管在指定不正确的情况下会有额外的可变性。对于尼古丁在香烟中评估中心项目 1 研究 2 的最后时间点的合规性,根据参与者的全部生物标志物历史进行条件处理,将接收器操作特性曲线下的面积提高了三个百分点。预测概率在一定程度上准确地逼近了非纵向合规概率。

讨论

与仅使用单个生物标志物测量的现有方法相比,我们的方法可以考虑生物标志物和合规性的纵向相关性,以更准确地识别不遵守规定的参与者。我们的方法还可以使用参与者的生物标志物历史来预测未来时间点的合规性。

相似文献

1
Detecting participant noncompliance across multiple time points by modeling a longitudinal biomarker.通过对纵向生物标志物进行建模来检测多个时间点的参与者不依从性。
Clin Trials. 2021 Feb;18(1):28-38. doi: 10.1177/1740774520956949. Epub 2020 Sep 14.
2
Estimating causal effects from a randomized clinical trial when noncompliance is measured with error.在测量不依从存在误差的情况下,从随机临床试验估计因果效应。
Biostatistics. 2018 Jan 1;19(1):103-118. doi: 10.1093/biostatistics/kxx029.
3
Efficiency and robustness of causal effect estimators when noncompliance is measured with error.当非依从性的测量存在误差时,因果效应估计的效率和稳健性。
Stat Med. 2018 Dec 10;37(28):4126-4141. doi: 10.1002/sim.7922. Epub 2018 Aug 14.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.流行病学方法与应用概述:观察性研究设计的优势与局限性。
Crit Rev Food Sci Nutr. 2010;50 Suppl 1(s1):10-2. doi: 10.1080/10408398.2010.526838.
6
Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods.在析因设计中对部分依从性和增加参与者负担进行二分法:四种不依从方法的表现。
Trials. 2015 Nov 17;16:523. doi: 10.1186/s13063-015-1044-z.
7
A fully Bayesian mixture model approach for identifying noncompliance in a regulatory tobacco clinical trial.一种用于识别监管烟草临床试验中不依从性的全贝叶斯混合模型方法。
Stat Med. 2020 Apr 30;39(9):1328-1342. doi: 10.1002/sim.8478. Epub 2020 Jan 21.
8
Classification Accuracy of Biomarkers of Compliance.依从性生物标志物的分类准确性。
Tob Regul Sci. 2019 May;5(3):301-319. doi: 10.18001/trs.5.3.8.
9
Double Robust Efficient Estimators of Longitudinal Treatment Effects: Comparative Performance in Simulations and a Case Study.纵向治疗效果的双重稳健有效估计量:模拟中的比较性能及一个案例研究
Int J Biostat. 2019 Feb 26;15(2):/j/ijb.2019.15.issue-2/ijb-2017-0054/ijb-2017-0054.xml. doi: 10.1515/ijb-2017-0054.
10
Biochemical estimation of noncompliance with smoking of very low nicotine content cigarettes.极低尼古丁含量香烟吸烟不依从性的生化评估。
Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):331-5. doi: 10.1158/1055-9965.EPI-14-1040. Epub 2014 Nov 21.

本文引用的文献

1
Classification Accuracy of Biomarkers of Compliance.依从性生物标志物的分类准确性。
Tob Regul Sci. 2019 May;5(3):301-319. doi: 10.18001/trs.5.3.8.
2
The Importance of Estimating Causal Effects for Evaluating a Nicotine Standard for Cigarettes.评估香烟尼古丁标准时估计因果效应的重要性。
Nicotine Tob Res. 2019 Dec 23;21(Suppl 1):S22-S25. doi: 10.1093/ntr/ntz119.
3
Randomized Trial of Low-Nicotine Cigarettes and Transdermal Nicotine.随机试验:低尼古丁香烟与经皮尼古丁。
Am J Prev Med. 2019 Oct;57(4):515-524. doi: 10.1016/j.amepre.2019.05.010.
4
Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial.香烟中尼古丁含量的即时减少与逐渐减少对吸烟暴露生物标志物的影响:一项随机临床试验。
JAMA. 2018 Sep 4;320(9):880-891. doi: 10.1001/jama.2018.11473.
5
Efficiency and robustness of causal effect estimators when noncompliance is measured with error.当非依从性的测量存在误差时,因果效应估计的效率和稳健性。
Stat Med. 2018 Dec 10;37(28):4126-4141. doi: 10.1002/sim.7922. Epub 2018 Aug 14.
6
Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes.极低尼古丁含量香烟中的尼古丁和去甲烟碱暴露
Tob Regul Sci. 2016 Apr;2(2):186-203. doi: 10.18001/TRS.2.2.9.
7
Estimating causal effects from a randomized clinical trial when noncompliance is measured with error.在测量不依从存在误差的情况下,从随机临床试验估计因果效应。
Biostatistics. 2018 Jan 1;19(1):103-118. doi: 10.1093/biostatistics/kxx029.
8
Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes.转向低尼古丁含量香烟者不依从性的估计与预测因素
Addiction. 2016 Dec;111(12):2208-2216. doi: 10.1111/add.13519. Epub 2016 Aug 1.
9
Quantitation of the Minor Tobacco Alkaloids Nornicotine, Anatabine, and Anabasine in Smokers' Urine by High Throughput Liquid Chromatography-Mass Spectrometry.采用高通量液相色谱 - 质谱法对吸烟者尿液中的微量烟草生物碱降烟碱、新烟草碱和假木贼碱进行定量分析。
Chem Res Toxicol. 2016 Mar 21;29(3):390-7. doi: 10.1021/acs.chemrestox.5b00521. Epub 2016 Feb 12.
10
Randomized Trial of Reduced-Nicotine Standards for Cigarettes.香烟降低尼古丁标准的随机试验
N Engl J Med. 2015 Oct;373(14):1340-9. doi: 10.1056/NEJMsa1502403.